NASDAQ:MEIP MEI Pharma (MEIP) Stock Price, News & Analysis $2.84 +0.44 (+18.13%) Closing price 07/3/2025 03:27 PM EasternExtended Trading$2.71 -0.13 (-4.55%) As of 07/3/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About MEI Pharma Stock (NASDAQ:MEIP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MEI Pharma alerts:Sign Up Key Stats Today's Range$2.37▼$2.6850-Day Range$1.99▼$2.8452-Week Range$1.46▼$4.10Volume53,769 shsAverage Volume44,311 shsMarket Capitalization$18.88 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California. Read More MEI Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreMEIP MarketRank™: MEI Pharma scored higher than 51% of companies evaluated by MarketBeat, and ranked 518th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for MEI Pharma.Read more about MEI Pharma's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for MEI Pharma are expected to grow in the coming year, from ($5.10) to ($3.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MEI Pharma is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MEI Pharma is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMEI Pharma has a P/B Ratio of 0.57. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about MEI Pharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.02% of the float of MEI Pharma has been sold short.Short Interest Ratio / Days to CoverMEI Pharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MEI Pharma has recently decreased by 51.85%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMEI Pharma does not currently pay a dividend.Dividend GrowthMEI Pharma does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.09 Percentage of Shares Shorted0.02% of the float of MEI Pharma has been sold short.Short Interest Ratio / Days to CoverMEI Pharma has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MEI Pharma has recently decreased by 51.85%, indicating that investor sentiment is improving significantly. News and Social MediaN/ANews SentimentN/A Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MEI Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.12% of the stock of MEI Pharma is held by insiders.Percentage Held by Institutions52.38% of the stock of MEI Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MEI Pharma's insider trading history. Receive MEIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MEI Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address MEIP Stock News HeadlinesMEI Pharma, Inc. (MEIP) Stock Price, Quote, News & Analysis - Seeking AlphaJune 26, 2025 | seekingalpha.comMEI Pharma Reports Third Quarter Fiscal Year 2025 Cash PositionMay 13, 2025 | businesswire.comThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.July 5 at 2:00 AM | Crypto Swap Profits (Ad)MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash PositionFebruary 12, 2025 | finance.yahoo.comMEI Pharma Registered ShsJanuary 22, 2025 | markets.businessinsider.comMEI Pharma (NASDAQ:MEIP) Stock, Option ChainNovember 18, 2024 | benzinga.comMEI Pharma Reports First Quarter Fiscal Year 2025 Cash PositionNovember 13, 2024 | finance.yahoo.comMEI Shares Rise After Entering Asset Purchase Agreement Valued at Up to $62 MillionOctober 25, 2024 | marketwatch.comSee More Headlines MEIP Stock Analysis - Frequently Asked Questions How have MEIP shares performed this year? MEI Pharma's stock was trading at $2.46 at the beginning of the year. Since then, MEIP shares have increased by 15.2% and is now trading at $2.8350. How were MEI Pharma's earnings last quarter? MEI Pharma, Inc. (NASDAQ:MEIP) released its earnings results on Tuesday, May, 13th. The company reported ($0.39) earnings per share (EPS) for the quarter. When did MEI Pharma's stock split? Shares of MEI Pharma reverse split before market open on Monday, April 17th 2023.The 1-20 reverse split was announced on Monday, April 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of MEI Pharma? Shares of MEIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MEI Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that MEI Pharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), CymaBay Therapeutics (CBAY) and Jabil (JBL). Company Calendar Last Earnings5/13/2025Today7/05/2025Next Earnings (Estimated)9/17/2025Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MEIP Previous SymbolNASDAQ:MSHL CIK1262104 Webwww.meipharma.com Phone(858) 369-7100Fax302-655-5049Employees100Year FoundedN/AProfitability EPS (Trailing Twelve Months)($4.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$17.78 million Net MarginsN/A Pretax MarginN/A Return on Equity-77.00% Return on Assets-64.79% Debt Debt-to-Equity RatioN/A Current Ratio16.78 Quick Ratio16.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$6.30 per share Price / Cash Flow0.45 Book Value$4.96 per share Price / Book0.57Miscellaneous Outstanding Shares6,660,000Free FloatN/AMarket Cap$18.88 million OptionableOptionable Beta0.19 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:MEIP) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MEI Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MEI Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.